Navigation Links
Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
Date:7/18/2012

BOSTON, July 18, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) today announced a new research collaboration with Brigham and Women's Hospital (BWH), a teaching and research affiliate of Harvard Medical School, focused on immunology of type 1 diabetes. The two organizations will share knowledge and apply their respective expertise in basic and applied research regarding diabetes and drug target and candidate development. 

(Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO )

Under the terms of the agreement, researchers from both organizations will undertake proof-of-concept, safety and functional studies for a novel immunomodulatory approach to treat type 1 diabetes. Sanofi has an option to exclusively license intellectual property emerging from this collaboration.

"Our engagement in this important research collaboration exemplifies our aim to help identify new treatment options and ultimately bring real benefits to people with type 1 diabetes," commented Pierre Chancel, Senior Vice President, Global Diabetes, Sanofi. "By working together to translate academic knowledge into know-how about a potential new drug target, we hope to discover revolutionary new options for patients living with type 1 diabetes worldwide."

Diabetes affects nearly 26 million people in the U.S. alone, with an estimated global prevalence of 346 million people(1,2) - a number which the World Health Organization projected would double between 2005 and 2030. In diabetes the body does not produce enough insulin, a hormone that regulates blood sugar, or cannot properly utilize the insulin it does make. It is the leading cause of kidney failure, a major cause of heart disease and stroke, and the seventh leading cause of death in the U.S.(1)

"Brigham and Women's Hospital is excited to engage in this important research collaboration," said Barbara Bierer, M.D., Senior Vice President of Research, Brigham and Women's Hospital. "This strategic collaboration brings further recognition to the outstanding research of the renowned Brigham scientist Vijay Kuchroo, D.V.M., Ph.D. and his colleagues including, Drs. Terry Strom and Maria Koulmanda from Beth Israel Deaconess Medical Center (BIDMC), and the importance of the translation of fundamental discoveries into routine clinical practice."

Financial details of the collaboration were not disclosed.  

About Sanofi Diabetes

Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services, and devices including innovative blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes. Investigational compounds in the pipeline include an injectable GLP-1 agonist being studied as a single agent, in combination with basal insulin, and/or in combination with oral anti-diabetic agents.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:
Sanofi R&D Communications
Elizabeth Baxter
Tel.: +1 908-981-5360
E-mail: Elizabeth.Baxter@sanofi.com

[1] Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2011. Atlanta, GA: U.S. Department of
Health and Human Services, Centers for Disease Control and Prevention, 2011. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf  Accessed on July 9, 2012

[2] World Health Organization Diabetes Fact Sheet No. 312, August 2011 Accessed at http://www.who.int/mediacentre/factsheets/fs312/en/index.html on July 9, 2012

 


'/>"/>
SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaVentures Client Sanofi Wins Scrip Outsourcing Deal of the Year Award
2. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
5. Bacterin Signs Distribution Agreement with Jeil for LeForte Craniomaxillofacial System
6. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
7. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
8. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
9. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
10. Agendia Signs Contract with Blue Shield of California
11. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
Breaking Biology Technology:
(Date:6/22/2016)... Md. , June 22, 2016  The American College ... Trade Show Executive Magazine as one of the ... on May 25-27 at the Bellagio in Las ... on the highest percentage of growth in each of the ... of exhibiting companies and number of attendees. The 2015 ACMG ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):